港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

湖南麦济生物技术股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

新股消息 | 麦济生物港股IPO招股书失效

科学家创业9年，烧钱8亿元！对赌上市倒计时仅剩1年，深陷专利纠纷的麦济生物如何撑起26亿元估值？

每日经济新闻

三生国健专利狙击麦济生物，估值26亿的IPO之路暗藏三重风险

三生国健与麦济生物专利战再开打

麦济生物港股IPO收证监会反馈意见：需说明股权变动合规性、专利纠纷影响等问题

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91209/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"91209","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","market":"HK","secType":"STK","nameCN":"湖南麦济生物技术股份有限公司（临时代码）","latestPrice":0,"timestamp":0,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"03-25 10:46:31","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774411200000},"marketStatusCode":2,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0,"lotSize":100,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91209\",,,,,undefined,":{"symbol":"91209","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91209\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91209\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91209\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91209\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603668855","title":"新股消息 | 麦济生物港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668855","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603668855?lang=zh_cn&edition=fundamental","pubTime":"2026-01-14 10:27","pubTimestamp":1768357655,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，湖南麦济生物技术股份有限公司-B(简称：麦济生物)于2025年7月14日所递交的港股招股书满6个月，于2026年1月14日失效，递表时中金为其独家保荐人。招股书显示，麦济生物是一家处于注册临床阶段的生物制药公司，专注于发现、开发及商业化创新生物制剂，以解决有关过敏性及自身免疫疾病以及其他炎症与免疫性疾病方面尚未满足的医疗需求。自2016年成立以来，公司已自主研发并建立一条由八款创新候选产品组成的强大管线，包括核心产品MG-K10、关键产品MG-014及MG-013，以及五款其他候选产品。所有该等产品均为通过公司自有技术平台发现及开发的新一代长效抗体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91209"],"gpt_icon":0},{"id":"2593457143","title":"科学家创业9年，烧钱8亿元！对赌上市倒计时仅剩1年，深陷专利纠纷的麦济生物如何撑起26亿元估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593457143","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593457143?lang=zh_cn&edition=fundamental","pubTime":"2025-12-23 09:51","pubTimestamp":1766454660,"startTime":"0","endTime":"0","summary":"临近年末，对递表港交所近半年却仍未进入聆讯的IPO公司而言，上市冲刺失败几率正在放大。公司今年7月14日向港交所提交上市申请书，截至目前尚未进入聆讯。自2016年成立以来，麦济生物已自主研发并建立一条由八款创新候选产品组成的管线。就在上个月，三生国健又提交了针对麦济生物一项核心专利无效宣告请求，是否会对MG-K10上市进程造成影响尚未可知。与此同时，麦济生物净亏损分别高达2.53亿元、","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-23/doc-inhctxhn8500511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161022","91209"],"gpt_icon":0},{"id":"2583490526","title":"三生国健专利狙击麦济生物，估值26亿的IPO之路暗藏三重风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2583490526","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583490526?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 13:34","pubTimestamp":1763098440,"startTime":"0","endTime":"0","summary":"三生国健与麦济生物围绕IL-4R抗体专利的争夺战再度升级。11月3日，三生国健公开表示，已向国家知识产权局申请宣告麦济生物核心专利无效，直指其当家产品MG-K10的命脉。这场纠纷背后，不仅是两家药企的技术归属之争，更暴露了麦济生物在冲刺港交所之际面临的专利、财务与市场竞争三重压力。三生国健随后提起诉讼，指控其为“职务发明”。　　麦济生物的财务状况同样令人担忧。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-14/doc-infxiwfa4569789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688336","91209"],"gpt_icon":0},{"id":"2580209904","title":"三生国健与麦济生物专利战再开打","url":"https://stock-news.laohu8.com/highlight/detail?id=2580209904","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580209904?lang=zh_cn&edition=fundamental","pubTime":"2025-11-04 14:34","pubTimestamp":1762238040,"startTime":"0","endTime":"0","summary":"　　三生国健与麦济生物的专利战有了新进展。　　三生国健表示，2020年，麦济生物的另一项IL-4R专利被上海知识产权法院判决侵权。当时，三生国健起诉麦济生物侵犯其专利权，称涉案专利技术实为职务发明，应归公司所有。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-04/doc-infwfiev0519233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688336","BK0239","91209"],"gpt_icon":0},{"id":"2571638353","title":"麦济生物港股IPO收证监会反馈意见：需说明股权变动合规性、专利纠纷影响等问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2571638353","media":"新浪证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571638353?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 16:40","pubTimestamp":1759135200,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　麦济生物IPO：8年烧8亿商业化进程仍无时间表 核心产品市场竞争激烈且专利曾陷权属纠纷。　　近日，麦济生物收到证监会关于本次境外上市的备案反馈意见，具体反馈如下，请你公司就以下事项补充说明，请律师核查并出具明确的法律意见：。　　一、关于股权变动。　　五、关于本次发行上市及“全流通”。　　7月14日，麦济生物向港交所递交主板上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-09-29/doc-infsecqp1764022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["YANG","07226","91209","HSTECH","HSCEI","BK4614"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}